A Three-Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation trial [5] is comparing upfront combined targeted therapy (encorafenib plus binimetinib) followed by combination immunotherapy (ipilimumab plus nivolumab) at disease progression (arm A) with upfront combination immunotherapy followed by combined targeted therapy at disease progression (arm B) in 209 patients with metastatic BRAF V600-mutant melanoma [37]. The gene discussed is BRAF; the disease is melanoma.